4.5 Article

Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction

期刊

ACS MEDICINAL CHEMISTRY LETTERS
卷 4, 期 3, 页码 353-357

出版社

AMER CHEMICAL SOC
DOI: 10.1021/ml300467n

关键词

WDR5; MLL; SET1 methyltransferase complex; peptide binding site; small molecule antagonists

资金

  1. Canadian Institutes for Health Research, Genome Canada [1097737]
  2. Canadian Foundation for Innovation
  3. Ontario Innovation Trust
  4. Ontario Ministry for Research and Innovation
  5. Wellcome Trust
  6. AbbVie
  7. Eli Lilly Canada
  8. GlaxoSmithKline
  9. Novartis
  10. Pfizer
  11. Takeda
  12. Government of Ontario through the Ontario Ministry of Economic Development and Innovation

向作者/读者索取更多资源

The WD40-repeat protein WDRS plays a critical role in maintaining the integrity of MLL complexes and fully activating their methyltransferase function. MLL complexes, the trithorax-like family of SET1 methyltransferases, catalyze trimethylation of lysine 4 on histone 3, and they have been widely implicated in various cancers. Antagonism of WDR5 and MLL subunit interaction by small molecules has recently been presented as a practical way to inhibit activity of the MLL1 complex, and N-(2-(4-methylpiperazin-1-yl)-5-substituted-phenyl) benzamides were reported as potent and selective antagonists of such an interaction. Here, we describe the protein crystal structure guided optimization of prototypic compound 2 (K-dis = 7 mu M), leading to identification of more potent antagonist 47 (K-dis = 0.3 mu M).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据